4//SEC Filing
Pershing Edward 4
Accession 0001493152-25-016223
CIK 0000315545other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 11:19 AM ET
Size
9.0 KB
Accession
0001493152-25-016223
Insider Transaction Report
Form 4
Pershing Edward
DirectorCEO
Transactions
- Exercise/Conversion
8% Unsecured Convertible Promissory Note
2025-09-30Exercise: $2.86From: 2024-09-30Exp: 2025-09-30→ Series D-1 Convertible Preferred Stock (66,052 underlying) - Exercise/Conversion
Series D-1 Convertible Preferred Stock
2025-09-30+66,052→ 2,484,499 totalFrom: 2025-09-30→ Common Stock (660,520 underlying)
Footnotes (4)
- [F1]Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
- [F2]The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
- [F3]The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2024 Note") at any time while the 2024 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2024 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2024 Note. The 2024 Note was issued pursuant to the Issuer's 2024 Financing.
- [F4]On September 30, 2025, the 2024 Note was converted into 66,052 shares of Series D-1 Preferred Stock.
Documents
Issuer
PROVECTUS BIOPHARMACEUTICALS, INC.
CIK 0000315545
Entity typeother
Related Parties
1- filerCIK 0001689739
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 11:19 AM ET
- Size
- 9.0 KB